Compared with hormone receptor (HR)-positive BC patients, Her2-positive BC patients show a high incidence of brain metastasis of more than 20 % [44], with an overall survival of 4-6 months with whole brain radiotherapy to about 18 months with multimodal therapies [45]. This evidence concerns the gene ERBB2 and breast cancer.